Coherus Oncology, Inc.
NASDAQ: CHRS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dennis Lanfear
- Employees
- 228
- Headquarters
- Redwood City, United States
- IPO year
- 2014
- Market cap
- $186.1M
- Website
- https://www.coherus.com
Loading CHRS…
Loading profile data…Frequently asked questions about CHRS
What does Coherus Oncology, Inc. (CHRS) do?
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neula...
Where does CHRS trade?
Coherus Oncology, Inc. (CHRS) trades on the NASDAQ Global Market.
What sector is CHRS in?
Coherus Oncology, Inc. (CHRS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Coherus Oncology, Inc.?
Dennis Lanfear is the chief executive officer of Coherus Oncology, Inc. (CHRS).
Where is Coherus Oncology, Inc. headquartered?
Coherus Oncology, Inc. is headquartered in United States.
Does CHRS pay a dividend?
Coherus Oncology, Inc. (CHRS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CHRS go public?
Coherus Oncology, Inc. (CHRS) completed its initial public offering in 2014.